RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

Rhea-AI Summary

RAPT Therapeutics, Inc. will participate in several investor conferences in November, including the Guggenheim Healthcare Talks, UBS BioPharma Conference, Piper Sandler Annual Healthcare Conference, and Evercore ISI HealthCONx Conference. The company will hold fireside chats at these conferences to discuss its immunology-based therapeutics for inflammatory diseases and oncology. Live webcasts and archived recordings will be available on the RAPT Therapeutics website.

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in November:

• Guggenheim Healthcare Talks: 5th Annual I&I Conference – Fireside chat on Tuesday, November 7, 2023 at 3:10 p.m. ET
  
• UBS BioPharma Conference 2023 – Fireside chat on Wednesday, November 8, 2023 at 4:00 p.m. ET
  
• Piper Sandler 35th Annual Healthcare Conference – Fireside chat on Tuesday, November 28, 2023 at 2:30 p.m. ET
  
• 6th Annual Evercore ISI HealthCONx Conference – Fireside chat on Wednesday, November 29, 2023 at 2:35 p.m. ET
  

To access the available live webcasts or subsequent archived recordings of the discussions, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, zelnecirnon (formerly RPT193) and tivumecirnon (formerly FLX475), each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com

Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com 

FAQ

What is the name of the company mentioned in the press release?

The company mentioned in the press release is RAPT Therapeutics, Inc.

What is the focus of RAPT Therapeutics, Inc.?

RAPT Therapeutics, Inc. focuses on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology.

What investor conferences will RAPT Therapeutics, Inc. participate in November?

RAPT Therapeutics, Inc. will participate in the Guggenheim Healthcare Talks, UBS BioPharma Conference, Piper Sandler Annual Healthcare Conference, and Evercore ISI HealthCONx Conference.

What will RAPT Therapeutics, Inc. do at these conferences?

RAPT Therapeutics, Inc. will hold fireside chats at these conferences to discuss their immunology-based therapeutics for inflammatory diseases and oncology.

Where can I access the webcasts and recordings of the discussions?

You can access the available live webcasts or subsequent archived recordings of the discussions on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.